Class Action Lawsuit Filed Against BioAge Labs, Inc. Following Disappointing Clinical Trial Results

The Law Offices of Howard G. Smith has initiated a class action lawsuit for individuals who purchased BioAge Labs, Inc. (“BioAge” or the “Company”) BIOA common stock linked to the Registration Statement from the Company’s September 2024 initial public offering (the “IPO” or the “Offering”). Investors have until March 10, 2025 to file a motion to become lead plaintiff.

Investors Affected by BioAge Labs, Inc. (BIOA) Losses Should Contact The Law Offices of Howard G. Smith

For further information regarding your legal rights, reach out to the Law Offices of Howard G. Smith via email at [email protected], call (215) 638-4847, or visit our website at www.howardsmithlaw.com.

Background on BioAge’s Situation

On or about September 2024, BioAge completed its IPO, selling 12.65 million shares at $18 each.

However, on December 6, 2024, the Company announced the discontinuation of its STRIDES Phase 2 study of the drug candidate azelaprag. This decision followed reports of liver transaminitis in some study participants.

The news caused BioAge’s stock to plummet by $15.44, representing a 76.85% drop, ending at $4.65 per share on December 9, 2024.

Since the IPO, investors have faced steep losses, with the stock trading at $5.82 per share—over 67% lower than the IPO price.

Details of the Lawsuit

The class action complaint alleges that during the Class Period, BioAge made false or misleading statements and failed to disclose critical negative information about its business operations and prospects. Allegations include: (1) a lack of disclosure about liver transaminitis observed in earlier clinical trials and preclinical studies; (2) failure to warn about safety issues in the ongoing STRIDES trial; (3) overestimating the likelihood of completing the STRIDES study; (4) exaggerating the potential of a second Phase 2 trial involving azelaprag and semaglutide for treating obesity; and (5) disseminating misleading positive statements about the Company’s overall condition.

How to Get Involved or Learn More

If you purchased BioAge securities, possess information about the matter, or have questions about your rights, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions according to applicable law and ethical standards.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20250110802485/en/

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com